<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="selinexor-rchop-ebv-dlbcl-cai">
    <meta name="study:title" content="PB3231 - First-line Selinexor in combination with R-CHOP for EBV-positive diffuse large B-cell lymphoma (Xplore): A single-arm, phase Ib/II trial">
    <meta name="study:fileName" content="Abstracts/SELINEXOR-RCHOP-EBV-DLBCL-CAI.html">
    <meta name="study:cancerTypes" content="DLBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="1L">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Selinexor,XPO1 inhibitor,Rituximab,Monoclonal Antibody,Cyclophosphamide,Doxorubicin,Vincristine,Prednisone,Chemotherapy,CIT,R-CHOP">

    <title>PB3231: Selinexor + R-CHOP in 1L EBV+ DLBCL (XPLORE) (Cai) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PB3231 - XPLORE Trial: Selinexor + R-CHOP in 1L EBV+ DLBCL</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=18)</h4>
                    <p>1L EBV+ DLBCL (18-80 yrs). Aim: Eval safety/efficacy of Selinexor + R-CHOP.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Intervention (Phase Ib/II)</h4>
                    <p>R-CHOP x6 (q21d) + Selinexor (from C2, RP2D 60mg QW). Then R+Selinexor x2. CR Pts → Selinexor maintenance.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path d="M3 13.5a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 13.5zM3 8.25a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 8.25zM3 18.75a.75.75 0 01.75-.75h16.5a.75.75 0 010 1.5H3.75A.75.75 0 013 18.75zM20.25 3a.75.75 0 00-.75.75v16.5a.75.75 0 001.5 0V3.75a.75.75 0 00-.75-.75z" />
                        <path fill-rule="evenodd" d="M9.97 4.28a.75.75 0 01.75-.75H12a.75.75 0 01.75.75v10.174l3.108-3.293a.75.75 0 111.084 1.038l-4.5 4.75a.75.75 0 01-1.084 0l-4.5-4.75a.75.75 0 111.084-1.038L9.97 14.454V4.28z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Efficacy (N=16 Evaluable)</h4>
                    <p>CR Rate: <span class="highlight-value">75%</span> (12/16)<br>ORR: <span class="highlight-value">94%</span> (15/16)<br>Median F/U: 12.6 mo</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Safety & Conclusion</h4>
                    <p>Acceptable safety. G3/4 Leukopenia/Neutropenia (67%). Promising efficacy. Further monitoring needed.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PB3231 - First-line Selinexor in combination with R-CHOP for EBV-positive diffuse large B-cell lymphoma (XPLORE): A single-arm, phase Ib/II trial</h1>
            <p class="abstract-sub-header">Qingqing Cai, Rong Tao, Yi Xia, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PB3231 | Publication Only</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>DLBCL is genetically and clinically heterogeneous.</li>
                        <li>Epstein-Barr virus (EBV) positivity (~8% of cases) is associated with inferior outcomes.</li>
                        <li>Selinexor (oral XPO1 inhibitor) showed preliminary efficacy with R-CHOP in NHL (Phase Ib).</li>
                        <li>XPLORE trial (NCT05577364): Single-arm, multicenter Phase Ib/II assessing Selinexor + R-CHOP in 1L EBV+ DLBCL.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To evaluate the safety and effectiveness of selinexor in combination with R-CHOP as first-line treatment in EBV-positive DLBCL patients.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Eligible: 18-80 yrs, pathologically diagnosed DLBCL, EBER positivity (FISH), measurable disease.</li>
                        <li>Treatment Regimen:
                            <ul class="list-circle list-inside ml-4">
                                <li>R-CHOP: Standard doses q21d x 6 cycles.</li>
                                <li>Selinexor: Initiated from C2. Phase Ib "3+3" design: 40mg QW (C2) → 60mg QW (C3+), if no DLTs.</li>
                                <li>Post-Induction: Rituximab + Selinexor x 2 cycles.</li>
                                <li>Maintenance (for CR Pts after 8 cycles induction): Selinexor.</li>
                            </ul>
                        </li>
                        <li>Primary Endpoints:
                            <ul class="list-circle list-inside ml-4">
                                <li>Phase Ib: MTD, RP2D.</li>
                                <li>Phase II: CR rate.</li>
                            </ul>
                        </li>
                         <li>Data cutoff: Feb 14, 2025.</li>
                    </ul>
                    <div class="study-design-schema">
                        <h3 class="schema-title">XPLORE Trial Design (Phase Ib/II)</h3>
                        <div class="schema-enrollment">
                            <strong>Eligible Patients (N=18 Enrolled)</strong>
                            <span>1L EBV+ DLBCL, 18-80 yrs</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%;">
                                <strong>Induction Therapy</strong>
                                <span><strong>C1:</strong> R-CHOP (q21d)</span>
                                <span><strong>C2:</strong> R-CHOP + Selinexor 40mg QW (Phase Ib "3+3")</span>
                                <span><strong>C3-C6:</strong> R-CHOP + Selinexor (escalated to 60mg QW if no DLTs) (q21d)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                         <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%;">
                                <strong>Consolidation (2 cycles)</strong>
                                <span>Rituximab + Selinexor</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group">
                            <div class="schema-phase" style="flex-basis: 100%;">
                                <strong>Maintenance (for CR Pts post-induction)</strong>
                                <span>Selinexor</span>
                            </div>
                        </div>
                         <div class="schema-assessment-points">
                           <span>Phase Ib: MTD, RP2D</span>
                           <span>Phase II: CR Rate</span>
                           <span>Safety (TRAEs)</span>
                        </div>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics (N=18)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value (n, %) or Median (range/IQR)</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Median Age, years (range)</td><td>56.5 (Abstract: 39-73 from table)</td></tr>
                                <tr><td>Gender - Female, n (%)</td><td>8 (44%)</td></tr>
                                <tr><td>Gender - Male, n (%)</td><td>10 (56%)</td></tr>
                                <tr><td>Ann Arbor Stage III-IV, n (%)</td><td>11 (61%)</td></tr>
                                <tr><td>IPI Score, n (%)</td><td></td></tr>
                                <tr><td class="pl-6">0-1</td><td>5 (28%)</td></tr>
                                <tr><td class="pl-6">2</td><td>10 (56%)</td></tr>
                                <tr><td class="pl-6">3</td><td>3 (17%)</td></tr>
                                <tr><td>Baseline Plasma EBV-DNA, copies/ml (median [IQR])</td><td>2,825 [310 - 13,175]</td></tr>
                            </tbody>
                        </table>
                        <p class="footnote-text mt-1">Median age in abstract text: 56.5 years. Table shows 56 (39-73). Using abstract text value where different.</p>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Efficacy Results (Median F/U: 12.6 months)</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2 mb-3">
                        <li>Patients completed median 7.5 combination treatment cycles (range 2-8).</li>
                        <li>RP2D of Selinexor: 60 mg once weekly. MTD not reached.</li>
                        <li><strong>Evaluable Patients (N=16):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>CR Rate: 75% (12/16)</li>
                                <li>ORR: 94% (15/16)</li>
                            </ul>
                        </li>
                    </ul>
                    <div class="chart-container mb-6">
                        <svg id="selinexorRCHOPResponseChart" width="350" height="280"></svg>
                        <div id="selinexorRCHOPResponseLegend" class="legend"></div>
                    </div>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Safety Summary (N=18)</h2>
                    <p class="text-sm mb-2">Common Treatment-Related Adverse Events (TRAEs) - Any Grade:</p>
                    <div class="table-container mb-3">
                        <table>
                            <thead>
                                <tr><th>TRAE</th><th>Any Grade, n (%)</th><th>Grade 3-4, n (%)</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Any TRAEs</td><td>16 (89%)</td><td>13 (72%)</td></tr>
                                <tr><td>Leukopenia</td><td>14 (78%)</td><td>12 (67%)</td></tr>
                                <tr><td>Neutropenia</td><td>14 (78%)</td><td>12 (67%)</td></tr>
                                <tr><td>Anemia</td><td>12 (67%)</td><td>4 (22%)</td></tr>
                                <tr><td>Thrombocytopenia</td><td>11 (61%)</td><td>7 (39%)</td></tr>
                                <tr><td>Nausea</td><td>7 (39%)</td><td>1 (6%)</td></tr>
                                <tr><td>Infection</td><td>5 (28%)</td><td>3 (17%)</td></tr>
                                <tr><td>Peripheral Neuropathy</td><td>4 (22%)</td><td>0</td></tr>
                            </tbody>
                        </table>
                    </div>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Dose reduction of Selinexor: 4 patients (22%).</li>
                        <li>Treatment interruption due to TRAEs: 3 patients (17%).</li>
                        <li>Treatment discontinuation due to TRAEs: 4 patients (22%). (Selinexor discontinuation from table: 2 G3/4)</li>
                        <li>No treatment-related deaths occurred.</li>
                    </ul>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>First-line Selinexor + R-CHOP demonstrated promising efficacy and an acceptable safety profile in EBV+ DLBCL.</li>
                <li>Further monitoring of selinexor-related toxicities is needed.</li>
                <li>The XPLORE trial is still recruiting, and evaluation is ongoing.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <p>CR, Complete Remission; DLBCL, Diffuse Large B-Cell Lymphoma; DLT, Dose-Limiting Toxicity; EBER, Epstein-Barr Encoding Region; EBV, Epstein-Barr Virus; F/U, Follow-up; FISH, Fluorescence In Situ Hybridization; IQR, Interquartile Range; MTD, Maximum Tolerated Dose; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; NHL, Non-Hodgkin Lymphoma; ORR, Overall Response Rate; PFS, Progression-Free Survival; QW, Once Weekly; R-CHOP, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; RP2D, Recommended Phase 2 Dose; TRAE, Treatment-Related Adverse Event; XPO1, Exportin 1.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Cai Q, Tao R, Xia Y, et al. First-line Selinexor in combination with R-CHOP for EBV-positive diffuse large B-cell lymphoma (XPLORE): A single-arm, phase Ib/II trial. Abstract #PB3231 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PB3231 | Abstract Release: 05/14/2025 | Presentation: 06/12/2025</p>
            <p>NCT05577364 | For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
    <script>
        function drawResponseChartPB3231(containerId, legendContainerId) {
            // N=16 evaluable: CR 75% (12/16), ORR 94% (15/16)
            // PR = ORR - CR = 94% - 75% = 19% (3/16)
            // Non-responders (SD/PD) = 100% - ORR = 100% - 94% = 6% (1/16)
            const chartData = {
                keys: ["CR", "PR", "Other (SD/PD)"], 
                values: { 
                    CR: 75.0, 
                    PR: 19.0, // Calculated: 94 (ORR) - 75 (CR) = 19
                    "Other (SD/PD)": 6.0 // Calculated: 100 - 94 (ORR) = 6
                }, 
                colors: ["var(--sobi-teal)", "var(--sobi-yellow)", "var(--sobi-medium-gray-text)"],
                orr: 94.0
            };
            const chartTitle = "Response Rate (N=16 Evaluable)";

            const svg = d3.select(containerId);
            const legendContainer = d3.select(legendContainerId);

            svg.selectAll("*").remove();
            legendContainer.selectAll("*").remove();

            let containerWidth = 350; 
            const chartWrapper = svg.node() ? svg.node().closest('.chart-container') : null;
            if (chartWrapper) {
                containerWidth = Math.max(chartWrapper.getBoundingClientRect().width * 0.85, 280);
            }
            
            const svgWidth = containerWidth;
            const svgHeight = +svg.attr("height"); 

            const margin = { top: 40, right: 20, bottom: 30, left: 50 };
            const chartWidth = svgWidth - margin.left - margin.right;
            const chartHeight = svgHeight - margin.top - margin.bottom;

            if (chartWidth <= 0 || chartHeight <= 0) return;

            const g = svg.append("g")
                .attr("transform", `translate(${margin.left},${margin.top})`);

            const categories = ["Response"];
            const stack = d3.stack().keys(chartData.keys.filter(key => chartData.values[key] > 0.09)); // Filter out very small values for stacking if needed
            const stackedData = stack([chartData.values]);

            const xScale = d3.scaleBand()
                .domain(categories)
                .range([0, chartWidth])
                .padding(0.6);

            const yScale = d3.scaleLinear()
                .domain([0, 100])
                .range([chartHeight, 0]);

            g.append("g")
                .attr("transform", `translate(0,${chartHeight})`)
                .call(d3.axisBottom(xScale).tickValues([]))
                .select(".domain").remove();

            g.append("g")
                .call(d3.axisLeft(yScale).ticks(5).tickFormat(d => d + "%"))
                .selectAll("text")
                .attr("class", "axis-text")
                .style("font-size", "10px");
            
            g.append("g")			
                .attr("class", "grid")
                .call(d3.axisLeft(yScale)
                    .ticks(5)
                    .tickSize(-chartWidth)
                    .tickFormat("")
                )
                .selectAll("line")
                .style("stroke", "#e0e0e0")
                .style("stroke-opacity", "0.7");

            const color = d3.scaleOrdinal()
                .domain(chartData.keys)
                .range(chartData.colors);

            g.selectAll(".serie")
                .data(stackedData)
                .enter().append("g")
                  .attr("class", "serie")
                .selectAll("rect")
                .data(d => d)
                .enter().append("rect")
                    .attr("x", d => xScale(categories[0]))
                    .attr("y", d => yScale(d[1]))
                    .attr("height", d => Math.max(0, yScale(d[0]) - yScale(d[1])))
                    .attr("width", xScale.bandwidth())
                    .attr("fill", (d, i, nodes) => {
                        const seriesKey = d3.select(nodes[i].parentNode).datum().key;
                        return color(seriesKey);
                    })
                    .attr("rx", 3).attr("ry", 3);
            
            stackedData.forEach((series) => {
                series.forEach((d) => {
                    const y0 = d[0];
                    const y1 = d[1];
                    const percentage = y1 - y0;
                    if (percentage > 5) { 
                        g.append("text")
                            .attr("class", "chart-label")
                            .attr("x", xScale(categories[0]) + xScale.bandwidth() / 2)
                            .attr("y", yScale(y0 + percentage / 2) + 4)
                            .attr("text-anchor", "middle")
                            .style("fill", (series.key === 'CR' && percentage > 15) || (series.key === 'PR' && percentage > 15) ? "white" : "var(--sobi-dark-text)") 
                            .style("font-size", "10px")
                            .style("font-weight", "bold")
                            .text(`${percentage.toFixed(0)}%`);// Use toFixed(0) for whole numbers if preferred
                    }
                });
            });
             if (chartData.orr) {
                 g.append("text")
                    .attr("class", "chart-label orr-label")
                    .attr("x", xScale(categories[0]) + xScale.bandwidth() / 2)
                    .attr("y", yScale(chartData.orr) - 8) 
                    .attr("text-anchor", "middle")
                    .style("font-weight", "600")
                    .style("font-size", "10px")
                    .style("fill", "var(--sobi-dark-blue)")
                    .text(`ORR: ${chartData.orr.toFixed(0)}%`);
            }
            
            svg.append("text")
                .attr("x", svgWidth / 2)
                .attr("y", margin.top / 2 + 5)
                .attr("text-anchor", "middle")
                .style("font-size", "13px")
                .style("font-weight", "600")
                .style("fill", "var(--sobi-dark-blue)")
                .text(chartTitle);

            const legendData = chartData.keys.filter(key => chartData.values[key] > 0.09).map(key => ({
                label: `${key} (${chartData.values[key].toFixed(0)}%)`,
                color: color(key)
            }));

            const legendItems = legendContainer.selectAll(".legend-item")
                .data(legendData).enter().append("div").attr("class", "legend-item");
            legendItems.append("div").attr("class", "legend-color-box").style("background-color", d => d.color);
            legendItems.append("span").text(d => d.label);
        }

        function debounce(func, wait) {
            let timeout;
            return function executedFunction(...args) {
                const later = () => {
                    clearTimeout(timeout);
                    func(...args);
                };
                clearTimeout(timeout);
                timeout = setTimeout(later, wait);
            };
        };

        const debouncedDrawChartPB3231 = debounce(() => drawResponseChartPB3231("#selinexorRCHOPResponseChart", "#selinexorRCHOPResponseLegend"), 250);
        
        window.addEventListener('resize', debouncedDrawChartPB3231);
        
        document.addEventListener('DOMContentLoaded', () => {
            debouncedDrawChartPB3231();
        });
        if (document.readyState === "complete" || document.readyState === "interactive") {
             setTimeout(debouncedDrawChartPB3231, 0); 
        }
    </script>
</body>
</html>
